ArticleCureus2025
The Incidence of Steroid-Induced Hyperglycemia in Pediatric Patients With Acute Lymphocytic Leukemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteroid-induced hyperglycemia (SIH) is a frequent but often overlooked complication in pediatric patients with acute lymphoblastic leukemia (ALL). Corticosteroid use, while essential for treatment, may result in transient or persistent elevations in blood glucose. This study aimed to determine the incidence of SIH and identify potential risk factors.
methodsA retrospective cohort study was conducted on 91 pediatric ALL patients receiving corticosteroids. Hyperglycemia was defined as blood glucose ≥200 mg/dL on at least two occasions, and borderline/transient hyperglycemia as levels between 140 and 199 mg/dL. Blood glucose was monitored throughout therapy, and demographic, clinical, and treatment variables were analyzed for associations with SIH.
resultsAmong the 91 patients, 11 (12.1%) developed hyperglycemia and 12 (13.2%) had transient/borderline hyperglycemia, while 68 (74.7%) remained normoglycemic. The onset of SIH occurred between days 2 and 16 of steroid therapy, with peaks on days 4 and 10. Patients receiving dexamethasone (82.4%) had slightly higher rates of hyperglycemia compared to those on prednisolone (17.6%), though not statistically significant (p = 0.663). Similarly, no significant associations were observed with age, gender, body mass index (BMI), or risk stratification. Higher steroid doses showed a trend toward increased risk, but without statistical significance (p = 0.985).
conclusionSIH occurred in approximately 1 in 8 pediatric ALL patients, though no significant risk factors were identified. These findings underscore the importance of routine glucose monitoring during corticosteroid therapy, regardless of patient demographics or regimen. Tailored surveillance and early intervention protocols are recommended to mitigate potential complications and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.